Oncology – Skin
Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management.
2 Sep, 2022 | 13:02h | UTC
3-year outcomes of a RCT | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma.
2 Sep, 2022 | 13:04h | UTCOriginal Study: Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
RCT | Optical coherence tomography vs. punch biopsy for diagnosis of basal cell carcinoma.
31 Aug, 2022 | 11:31h | UTCOptical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
RCT | Talimogene Laherparepvec plus Pembrolizumab not better than placebo-Pembrolizumab in patients with advanced melanoma.
26 Aug, 2022 | 13:09h | UTC
RCT | Therapeutic value of sentinel lymph node biopsy in patients with melanoma.
4 Aug, 2022 | 14:05h | UTCTherapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited Commentary: Prognostic or Therapeutic—The Role of Sentinel Lymph Node Biopsy in Contemporary Practice – JAMA Surgery (free for a limited period)
Cohort Study | Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas.
1 Aug, 2022 | 12:03h | UTCCommentary: Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ – AJMC
Cohort Study | Clinical outcomes and risk stratification of early-stage melanoma micrometastases.
1 Aug, 2022 | 12:04h | UTCClinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
‼️ Patients with low-risk (pT1b-pT2a) #melanoma may still develop high-risk sentinel node metastases ➡️ https://t.co/cBVdpR6xrG #JCO #melsm @marc_moncrieff pic.twitter.com/TW0WHp5brA
— Journal of Clinical Oncology (@JCO_ASCO) July 27, 2022
Single-arm phase 2 study | Lenvatinib plus Pembrolizumab for melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given as monotherapy or in combination.
1 Aug, 2022 | 11:48h | UTCPhase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression — More than a fifth of patients responded to lenvatinib-pembrolizumab combination – MedPage Today (free registration required)
NICE Guideline Update | Melanoma: assessment and management.
28 Jul, 2022 | 13:21h | UTCMelanoma: assessment and management – National Institute for Health and Care Excellence
RCT | Efficacy and safety of topical hypericin photodynamic therapy for early-stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides).
28 Jul, 2022 | 13:09h | UTCEfficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Commentary on Twitter
The findings of this randomized clinical trial indicate that synthetic hypericin photodynamic therapy is effective in early-stage patch and plaque mycosis fungoides−cutaneous T-cell lymphoma and has a favorable safety profile. https://t.co/hHfDESptQF
— JAMA Dermatology (@JAMADerm) July 21, 2022
RCT | Follow-up schedule for patients with sentinel node negative cutaneous melanoma.
25 Jul, 2022 | 12:43h | UTCFollow-up Schedule for Patients with Sentinel Node Negative Cutaneous Melanoma: an International Phase III Randomised Clinical Trial – Annals of Surgery (link to abstract – $ for full-text)
5-year outcomes of a RCT | Encorafenib plus Binimetinib vs. Vemurafenib or Encorafenib in patients with BRAF V600–mutant melanoma.
25 Jul, 2022 | 12:41h | UTC
M-A | Does it really pay-off? Comparison of lymphadenectomy versus observational approach in skin melanoma with positive sentinel node biopsy.
12 Jul, 2022 | 12:37h | UTC
M-A | Associations of thiazide use with skin cancers.
8 Jul, 2022 | 11:55h | UTCAssociations of thiazide use with skin cancers: a systematic review and meta-analysis – BMC Medicine
Related:
Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma – JAMA Internal Medicine
M-A | Adjuvant treatments of adult melanoma.
7 Jul, 2022 | 12:12h | UTC
Consensus Guideline: Diagnosis and treatment of Merkel cell carcinoma.
28 Jun, 2022 | 11:07h | UTC
Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.
23 Jun, 2022 | 09:57h | UTC
ASCO Guideline Update: Systemic therapy for melanoma.
14 Jun, 2022 | 11:00h | UTC
Systematic Review: Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings.
10 Jun, 2022 | 10:28h | UTC
Commentary on Twitter
NEW Review: '#ArtificialIntelligence and #MachineLearning algorithms for early detection of #skincancer in community and primary care settings: a systematic review'. @Cambridge_Uni @OUHospitals @UniMelb @UniofNottingham @QMUL_WIPH https://t.co/LQuzNbrKpn pic.twitter.com/v83GDEg2G4
— The Lancet Digital Health (@LancetDigitalH) May 26, 2022
RCT: Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma.
2 Jun, 2022 | 10:41h | UTC
Commentary on Twitter
In this RCT, adjunctive use of reflectance confocal microscopy for suspicious lesions is proven to reduce unnecessary excisions and removes all aggressive melanomas at baseline in a real-life, prospective clinical decision making setting. https://t.co/cWJu9TlaEH
— JAMA Dermatology (@JAMADerm) June 1, 2022
Review: Managing metastatic melanoma in 2022.
19 May, 2022 | 10:23h | UTCManaging Metastatic Melanoma in 2022: A Clinical Review – JCO Oncology Practice
Commentary on Twitter
Managing Metastatic #Melanoma in 2022: Clinical Review
A comprehensive guide to past, present, and future therapeutic approaches for patients with #advancedmelanoma. https://t.co/lh02gmmY27 #melsm #JCOOP @BenSwitzerDO pic.twitter.com/8V4bqcsMGT
— JCO Oncology Practice (@JCOOP_ASCO) February 23, 2022
Cohort Study: Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis.
5 May, 2022 | 10:14h | UTCRecurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis – JAMA Dermatology (link to abstract – $ for full-text)
Author Interview: Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis
News Release: Patients with rare skin cancer, Merkel cell carcinoma, face 40% recurrence rate – University of Washington School of Medicine
Commentary on Twitter
In this cohort study, Merkel cell carcinoma (MCC) recurrence rate was 40%, more than 90% of MCC recurrences arose within 3 years. https://t.co/46rDnVtyHh
— JAMA Dermatology (@JAMADerm) February 23, 2022
Guidelines: Cutaneous lymphomas.
25 Apr, 2022 | 00:38h | UTC
RCT: Pembrolizumab vs. placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma.
4 Apr, 2022 | 00:56h | UTCPembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Global burden of cutaneous melanoma in 2020 and projections to 2040.
31 Mar, 2022 | 08:11h | UTCGlobal Burden of Cutaneous Melanoma in 2020 and Projections to 2040 – JAMA Dermatology (free for a limited period)
Editorial: Melanoma Epidemiology—Pivoting to Low- and Middle-Income Countries (free for a limited period)
Commentary: Global Burden of Melanoma Considerable, Set to Rise by 2040 – HealthDay